Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21704520 | 0.86 | ALDH1A1 (0.46) | MAPTALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL21704471 | 0.83 | ADORA2B (0.58) | MAPTALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL21704331 | 0.83 | ALDH1A1 (0.44) | MAPTALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL30726179 | 0.77 | SMN1; SMN2 (0.42) | MAPTALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL26620710 | 0.77 | SMN1; SMN2 (0.42) | MAPTALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL25366055 | 0.74 | MAPT (0.41) | MAPTALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL30558043 | 0.74 | MAPT (0.41) | MAPTALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL30558061 | 0.73 | SMN1; SMN2 (0.39) | MAPTALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL25365319 | 0.73 | SMN1; SMN2 (0.39) | MAPTALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL30558064 | 0.73 | SMN1; SMN2 (0.39) | MAPTALDH1A1KMT2AMEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-07-20 | — | — | US | disclosed |
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ADORA2A, ADORA2B, ADORA3 | MAPT 3153/4885ALDH1A1 939/4885KMT2A 2625/4885 |
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | ADORA2A, ADORA2B, ADORA3 | MAPT 3153/4885ALDH1A1 939/4885KMT2A 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.